Patents by Inventor Ratna K. Vadlamudi

Ratna K. Vadlamudi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OLIGO-BENZAMIDE ANALOGS AND THEIR USE IN CANCER TREATMENT
    Publication number: 20220017454
    Abstract: The present disclosure compounds of the formulae: wherein the variables are defined herein, as well as pharmaceutical compositions thereof. The present disclosure also provides methods for the use of said compounds and/or pharmaceutical compositions, such as in the treatment of cancer.
    Type: Application
    Filed: June 3, 2021
    Publication date: January 20, 2022
    Applicant: Board of Regents, The University of Texas System
    Inventors: Ganesh RAJ, Jung-Mo AHN, Ratna K. VADLAMUDI
  • Targeting of PELP1 in cancer therapy
    Patent number: 10682388
    Abstract: The disclosure describes PELP1 binding peptides and peptoids and their use the interaction of PELP1 with molecules that lead to oncogenic signaling in cancers.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: June 16, 2020
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Ratna K. Vadlamudi, Monica Mann, Samaya Krishnan, Gangadhara Reddy Sareddy
  • TARGETING OF PELP1 IN CANCER THERAPY
    Publication number: 20170165320
    Abstract: The disclosure describes PELP1 binding peptides and peptoids and their use the interaction of PELP1 with molecules that lead to oncogenic signaling in cancers.
    Type: Application
    Filed: January 14, 2015
    Publication date: June 15, 2017
    Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Ratna K. VADLAMUDI, Monica MANN, Samaya KRISHNAN, Gangadhara Reddy SAREDDY
  • Oligo-benzamide compounds for use in treating cancers
    Patent number: 8835493
    Abstract: The present invention provides bis- and tris-benzamide compounds in the treatment of breast, brain and ovarian cancers.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: September 16, 2014
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jung-Mo Ahn, Ratna K. Vadlamudi, Ganesh Raj
  • p62 polypeptides, related polypeptides, and uses therefor
    Patent number: 6291645
    Abstract: Isolated nucleic acid molecules encoding novel members of the p62 family of polypeptides which include, in preferred embodiment, an SH2 binding domain and a ubiquitin binding domain are described. Also disclosed are novel members of the p160 family of polypeptides. The p62 polypeptides and the p160 polypeptides of the invention are capable of modulating leukocyte activity, e.g., by stimulating a B cell response, including B cell proliferation, B cell aggregation, B cell differentiation, B cell survival, and/or stimulating a T cell response, e.g., T cell proliferation, T cell aggregation, T cell differentiation, and T cell survival, are disclosed. The p62 polypeptides and the p160 polypeptides of the invention are also capable of modulating ubiquitin-mediated degradation of cellular proteins.
    Type: Grant
    Filed: July 19, 1999
    Date of Patent: September 18, 2001
    Assignee: Dana-Farber Cancer Institute
    Inventors: Jaekyoon Shin, Insil Joung, Ratna K. Vadlamudi, Jack L. Strominger
  • Isolated DNA encoding p62 polypeptides and uses therefor
    Patent number: 5962224
    Abstract: Isolated nucleic acid molecules encoding novel members of the p62 family of polypeptides which include, in preferred embodiment, an SH2 binding domain and a ubiquitin binding domain are described. Also disclosed are novel members of the p160 family of polypeptides. The p62 polypeptides and the p160 polypeptides of the invention are capable of modulating leukocyte activity, e.g., by stimulating a B cell response, including B cell proliferation, B cell aggregation, B cell differentiation, B cell survival, and/or stimulating a T cell response, e.g., T cell proliferation, T cell aggregation, T cell differentiation, and T cell survival, are disclosed. The p62 polypeptides and the p160 polypeptides of the invention are also capable of modulating ubiquitin-mediated degradation of cellular proteins.
    Type: Grant
    Filed: December 19, 1995
    Date of Patent: October 5, 1999
    Assignee: Dana-Farber Cancer Institute
    Inventors: Jaekyoon Shin, Insil Joung, Ratna K. Vadlamudi, Jack L. Strominger